Literature DB >> 18559124

Effectiveness of vaccinating household contacts in addition to chemoprophylaxis after a case of meningococcal disease: a systematic review.

M R Hoek1, H Christensen, W Hellenbrand, P Stefanoff, M Howitz, J M Stuart.   

Abstract

SUMMARYWe performed a systematic review to estimate the effectiveness of vaccination, in addition to chemoprophylaxis, in preventing meningococcal disease among household contacts. Medline, EMBASE, EMGM, and EUIBIS were used for data collection. Studies reporting on at least 100 primary cases and on subsequent cases in household settings with follow-up of more than 2 weeks after onset of disease in the primary case were reviewed. A meta-analysis was used to calculate the average attack rate in household contacts given chemoprophylaxis 14-365 days after onset of disease in the primary case. In total, 652 studies were identified, five studies and one unpublished report met the inclusion criteria. The weighted average attack rate was 1.1/1000 household contacts (95% CI 0.7-1.7). This review supports vaccination of household contacts in addition to chemoprophylaxis to reduce the risk of meningococcal disease among household contacts of a case caused by a vaccine-preventable serogroup.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18559124      PMCID: PMC2870749          DOI: 10.1017/S0950268808000770

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  24 in total

1.  Policies for public health management of meningococcal disease.

Authors:  N Begg
Journal:  J Epidemiol Community Health       Date:  1999-09       Impact factor: 3.710

2.  Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease.

Authors:  Philippe De Wals; Van Hung Nguyen; Lonny J Erickson; Maryse Guay; Jean Drapeau; Jennifer St-Laurent
Journal:  Vaccine       Date:  2004-03-12       Impact factor: 3.641

3.  Spread of meningococcal infection within households.

Authors:  R S Munford; A de E Taunay; J S de Morais; D W Fraser; R A Feldman
Journal:  Lancet       Date:  1974-06-22       Impact factor: 79.321

4.  Should college students be vaccinated against meningococcal disease? A cost-benefit analysis.

Authors:  L A Jackson; A Schuchat; R D Gorsky; J D Wenger
Journal:  Am J Public Health       Date:  1995-06       Impact factor: 9.308

5.  Clusters of meningococcal disease in school and preschool settings in England and Wales: what is the risk?

Authors:  K L Davison; N Andrews; J M White; M E Ramsay; N S Crowcroft; A A Rushdy; E B Kaczmarski; P N Monk; J M Stuart
Journal:  Arch Dis Child       Date:  2004-03       Impact factor: 3.791

6.  Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction.

Authors:  Caroline L Trotter; Nick J Andrews; Edward B Kaczmarski; Elizabeth Miller; Mary E Ramsay
Journal:  Lancet       Date:  2004 Jul 24-30       Impact factor: 79.321

7.  The number needed to vaccinate (NNV) and population extensions of the NNV: comparison of influenza and pneumococcal vaccine programmes for people aged 65 years and over.

Authors:  Heath Kelly; John Attia; Ross Andrews; Richard F Heller
Journal:  Vaccine       Date:  2004-06-02       Impact factor: 3.641

8.  [Secondary cases of meningococcal disease in The Netherlands, 1989-1990; a reappraisal of chemoprophylaxis].

Authors:  R J Scholten; H A Bijlmer; J Dankert; H A Valkenburg
Journal:  Ned Tijdschr Geneeskd       Date:  1993-07-24

Review 9.  Effectiveness of antibiotics in preventing meningococcal disease after a case: systematic review.

Authors:  Bernadette Purcell; Susanne Samuelsson; Susan J M Hahné; Ingrid Ehrhard; Sigrid Heuberger; Ivonne Camaroni; André Charlett; James M Stuart
Journal:  BMJ       Date:  2004-06-05

10.  Space-time cluster analysis of invasive meningococcal disease.

Authors:  Christian J P A Hoebe; Hester de Melker; Lodewijk Spanjaard; Jacob Dankert; Nico Nagelkerke
Journal:  Emerg Infect Dis       Date:  2004-09       Impact factor: 6.883

View more
  3 in total

1.  Meningococcal disease serogroup C.

Authors:  Félix O Dickinson; Antonio E Pérez; Iván E Cuevas
Journal:  Risk Manag Healthc Policy       Date:  2012-03-08

2.  Two Cases of Meningococcal Disease in One Family Separated by an Extended Period - Colorado, 2015-2016.

Authors:  Emily Spence Davizon; Heidi M Soeters; Lisa Miller; Meghan Barnes
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-03-30       Impact factor: 17.586

Review 3.  Chemoprophylaxis and vaccination in preventing subsequent cases of meningococcal disease in household contacts of a case of meningococcal disease: a systematic review.

Authors:  L Telisinghe; T D Waite; M Gobin; O Ronveaux; K Fernandez; J M Stuart; R J P M Scholten
Journal:  Epidemiol Infect       Date:  2015-04-28       Impact factor: 4.434

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.